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Abstract
Background:  A previous report showed that the atypical neuroleptic clozapine resulted in
marked changes in urodynamic parameters and greatly inhibited the activity of the external urethral
sphincter in anesthetized rats. Such findings may help explain the high incidence of urinary
disturbances reported during clozapine therapy. In an effort to extend our observations to other
atypical neuroleptic agents, the present study investigated the effects of two newer atypical
antipsychotics, olanzapine and risperidone, on the bladder and external urethral sphincter during
cystometry in anesthetized rats.
Results:  At a dose of 0.1 mg/kg (i.v.), olanzapine decreased the micturition volume and increased
the residual volume. In addition, olanzapine decreased the expulsion time and the amplitude of the
high frequency oscillations observed during the expulsion phase. Larger doses (1 mg/kg) had a
greater effect. Olanzapine also reduced the activity recorded from the external urethral sphincter,
and the bursting observed during the expulsion phase was abolished by 1.0 mg/kg. Risperidone had
similar effects although the maximal effects were smaller than those observed with olanzapine. The
amplitude of bladder contractions elicited by electrical stimulation of the pelvic nerve was reduced
by olanzapine but not risperidone suggesting a possible anti-muscarinic peripheral effect of
olanzapine.
Conclusions:  Olanzapine and risperidone significantly altered several voiding parameters and
decreased the activity of the external urethral sphincter in the anesthetized rat. We propose that
these effects are due to the central action of these drugs and not to peripheral effects. These
findings may explain some of the clinical reports of urinary incontinence with risperidone and may
predict similar occurrences with olanzapine therapy.
Background
The lower urinary tract serves to store and periodically
eliminate urine. The activity of the urinary bladder and
the external urethral sphincter must be properly coordi-
nated in order for continence to be maintained and time-
ly micturition to occur. Effective micturition requires the
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coordination of central and peripheral nervous system
structures that activate sympathetic, parasympathetic
and somatic motor pathways innervating the bladder
and the urethra (for a recent review see [1]). Pathophys-
iological conditions and pharmacological manipulations
that affect central and/or peripheral nervous system
structures involved in micturition may alter the function
of these two organs [2].
Atypical antipsychotic (neuroleptic) agents are favored
over traditional antipsychotic medication (e.g. haloperi-
dol) because of their lower incidence of extrapyramidal
side effects, their greater efficacy in improving negative
symptoms of schizophrenia, and their effectiveness in
treating schizophrenic patients not responding to con-
ventional neuroleptics [3]. However, side effects contin-
ue to pose a challenge to effective treatment [4]. These
novel neuroleptics display a complex pharmacological
profile with affinities for several receptor systems but are
generally characterized by a greater affinity for the 5-
HT2A receptor than for the target of the traditional neu-
roleptics, the D2 receptor [4,5].
We have shown recently that the atypical antipsychotic
clozapine, and to a lesser extent haloperidol, markedly
influenced several micturition parameters in anesthe-
tized rats [6]. Clozapine decreased the micturition vol-
ume while increasing bladder capacity, thus increasing
residual volume [7]. Moreover, clozapine profoundly de-
pressed the activity of the external urethral sphincter
(EUS). Clozapine abolished the electromyogram (EMG)
recorded from the EUS during the rising phase of a blad-
der contraction before urine is voided (similar to the
"guarding reflex" [8,9]). In addition, clozapine also abol-
ished the high frequency oscillations in the bladder pres-
sure and accompanying bursts in the external urethral
sphincter EMG, that are present during the expulsion
phase of the micturition profile of the rat [7]. In the clin-
ical literature, clozapine therapy is associated with a high
incidence (up to 44% in a recent study [10]) of urinary in-
continence and enuresis.
Olanzapine is a newer atypical antipsychotic agent with a
pharmacological profile very similar to that of clozapine
[11]. In human brain tissue, olanzapine displays very
high affinity for the H1 histamine receptor, high affinity
for 5-HT2A and 5-HT2C receptors [12]. In addition it
also shows affinity for D2, muscarinic, and alpha1 recep-
tors, with lower affinity for alpha2, 5-HT1D and 5-HT1A
receptors (Table 1 [12]).
Olanzapine therapy is associated with a number of side
effects, including somnolence, agitation, nervousness,
headaches, dizziness, weight gain, constipation and dry
mouth [5]. Olanzapine, however, does not produce ex-
trapyramidal side effects, postural hypotension or hemo-
toxicity (a particular problem for patients on clozapine
therapy [13]). Although urinary retention as a result of
olanzapine therapy may be predicted from binding stud-
ies due to olanzapine's antimuscarinic activity [12] only 1
case report of micturition disturbance associated with
olanzapine has recently appeared [14]. On the other
hand, several reports of urinary disturbances due to cloz-
apine can be found in the clinical literature [3,10,15].
Risperidone, another novel atypical neuroleptic, shows
very high affinity for 5HT-2A receptors with lower affin-
ity for D2 receptors. In terms of profile risperidone binds
5HT2A>>alpha1=H1>D2>alpha2 (Table 1[12,16]). Risp-
eridone displays little or no affinity for the muscarinic re-
ceptor [11,12,16] and yet risperidone therapy has been
associated with urinary incontinence (28% in some cases
[17–19]).
We undertook this study to examine the effects of olan-
zapine and risperidone on the cystometrogram of anes-
thetized rats. These two novel atypical neuroleptic
compounds are used in clinical practice and it might be
important to identify possible side effects that may have
an impact on compliance to therapy or adversely affect
the patient's quality of life (e.g. persistent urinary incon-
tinence). Based on our previous findings with clozapine,
and given the similarity in pharmacological profiles be-
tween olanzapine and clozapine, we hypothesized that
olanzapine might also result in changes in urodynamic
variables and/or external urethral sphincter EMG. Risp-
eridone provides an interesting comparison to olanzap-
ine since it has a similar pharmacological profile to
olanzapine but without the antimuscarinic activity. In
this study olanzapine had greater effects than risperi-
done but both decreased micturition volume and in-
creased residual volume in anesthetized rats. In
Table 1: Dissociation constants (nmoles) at human brain recep-
tors. Data from [12]
Olanzapine Risperidone
α 1 44 2.7
α 2 280 8
D2 20 3.77
H1 0.087 5.2
Muscarinic 36 34000
5-HT1A 610 190
5-HT1D 150 3.9
5-HT2A 1.48 0.15
5-HT2C 4.1 32BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
addition, they inhibited the activity of the external ure-
thral sphincter. Olanzapine, but not risperidone, also
had peripheral effects that reduced bladder contraction
amplitude to electrical stimulation of the pelvic nerve.
Results
Effects of olanzapine and risperidone on single cystometry 
parameters (Tables 2 and 3)
Olanzapine had no effect on bladder capacity (Fig 3A)
and risperidone increased BC only at the highest dose (10
mg/kg; Fig 2I,J; 3A) when the bladder capacity was 0.54
ml (S.E.M = ±0.08; Table 3) compared to 0.35 ml
(±0.097) for vehicle-injected control.
Micturition volume, however, was decreased by both
olanzapine and risperidone. The mean micturition vol-
ume in the olanzapine group after administration of ve-
hicle was 0.2 ml (±0.0.37). However, after 0.1 and 1.0
mg/kg the micturition volume dropped to 0.08 ml
(±0.014) and 0.04 ml (±0.006), respectively (Fig. 3B; Ta-
ble 2). Similarly, the risperidone group had a mean mic-
turition volume of 0.27 ml (±0.072) after vehicle
injection, but there was a significant decrease to 0.1 ml
(±0.019) and 0.12 ml (±0.016) after 0.1 and 1.0 mg/kg of
risperidone (Fig. 3B; Table 3). At 10 mg/kg of risperi-
done, the micturition volume was 0.19 ml (± 0.036)
which was not statistically different from the control val-
ues.
Consequently, the residual volume showed significant
increases after 0.1 and 1 mg/kg doses of olanzapine (76 ±
5.3 and 89 ± 2.4%, respectively; Fig 3C) and after all dos-
es of risperidone (maximal effect at 0.1 mg/kg; 70 ±
7.8%; Fig. 3C).
Olanzapine had no effect on pressure threshold; howev-
er, risperidone at 1 and 10 mg/kg resulted in a significant
increase in the pressure threshold (5.0 ± 1.02 and 5.8 ±
1.02 mm Hg, respectively; Fig. 4A) compared to the value
observed during administration of vehicle (2.4 ± 0.62
mm Hg). The peak pressure during contraction was not
changed by any of the doses of olanzapine tested in this
study (Fig. 4B). Interestingly, 10 mg/kg of risperidone
showed a modest, but statistically significant increase in
peak contraction pressure (13.7 ± 1.34 mm Hg compared
to control value of 11.5 ± 0.95 mm Hg; Fig. 4B).
The contraction time was not affected by either olanzap-
ine or risperidone (Fig. 5A) but the expulsion time (the
time during which the HFO occur) was significantly de-
creased by both (Fig. 1; Fig. 2; Fig. 5B). Olanzapine de-
creased the expulsion time from 2.6 (±0.55) sec after
vehicle injection to 0.9 (±0.38) and 0 sec after 0.1 and 1.0
mg/kg, respectively (Fig. 5B). The risperidone group had
an expulsion time of 3.6 (±0.83) sec after control and it
decreased to 1.5 (±0.34) and 1.4 (±0.35) sec after 0.1 and
1 mg/kg of risperidone (Fig 5B). At 10 mg/kg of risperi-
done, the expulsion time was 2.2 (± 0.46) sec.
Similarly, olanzapine significantly decreased the ampli-
tude of high frequency oscillations (HFO) from a control
value of 1.6 (±0.19) to 1.0 (±0.38) mm Hg at 0.1 mg/kg
and abolished the HFO in all animals tested at 1 mg/kg
(Fig. 1; 5C). Risperidone also reduced the amplitude of
the HFO from 1.6 (±0.19) to 1.0 (±0.22), 0.9 (±0.18) and
Table 2: Effects of cumulative doses of olanzapine on urodynamic and EMG parameters in anesthetized rats. Values are Mean ± S.E.M. 
Urodynamic parameters EUS EMG parameters
Dose BC (ml) MV (ml) RV (%) PT PP CT ET  HFO Phase 1 Phase 2 Phase 3 Burst
(mg/kg) (mm Hg) (mm Hg) (sec) (sec) (mm Hg) (%) (%) (%) Amp. 
(%)
Control 0.28 0.20 26 4.1 14.3 16.8 2.6 1.6 100 100 100 100
(±0.046) (±0.037) (±8.7) (±0.93) (±1.26) (±0.61) (±0.55) (±0.19)
0.01 0.30 0.22 23 5.5 13.6 17.0 3.3 1.6 80 138 94 (±4.6) 105
(±0.049) (±0.045) (±10.8) (±0.96) (±0.90) (±1.57) (±0.63) (±0.17) (±14.0) (±23.4) (±3.2)
0.1 0.39 0.08* 76** 4.9 14.6 17.1 0.9** 1.0* 76* 42** 69** 72
(±0.064) (±0.014) (±5.3) (±1.52) (±0.91) (±0.91) (±0.38) (±.42) (±1.9) (±11.4) (±12.6) (±19.2)
1 0.38 0.04** 89** 6.84 12.7 17.38 0** 0** 47** 0** 35** 0**
(±0.072) (±0.006) (±2.4) (±1.79) (±1.24) (±2.60) (±6.0) (±5.2)
* p < 0.05; ** p < 0.01BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
Figure 1
Representative traces of the effects of cumulative intravenous doses of olanzapine on the cystometrograms (CMG) and exter-
nal urethral sphincter EMG of anesthetized rats (n = 5). Top panel presents bladder pressure during CMG while bottom panel
is integrated EMG recorded from the external urethral sphincter. Panels A and B also show the different parameters recorded
from the CMG: BC = amount of fluid infused to elicit a contraction; PT = pressure at which contraction begins; PP = maximal
pressure during contraction; CT= contraction time; ET = time between peak pressure and end of high frequency oscillations.
The EMG activity was examined by dividing the bladder contraction into three phases in a modification of the technique of
Chien et al. [32] a contraction phase (phase 1); an expulsion phase (phase 2) and a closing phase (phase 3). A) CMG following
administration of control (saline). (B) Expanded time scale showing the expulsion phase and the high frequency oscillations
(HFO) in the bladder record, with accompanying bursting in the EMG. C & D) 0.01 mg/kg of olanzapine does not have an effect
on the CMG or the external urethral sphincter EMG. E & F) After 0.1 mg/kg of olanzapine, the amplitude of the HFO is dimin-
ished and the expulsion time is shortened. G & H) 1 mg/kg of olanzapine abolished HFO, there is no discernible expulsion time
and the EMG record shows no bursting and a much lower level of activity compared to control. Calibration bar: A,C,E,G = 1
min; B,D,F,H = 1 sec.BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
1.1 (± 0.22) mm Hg after 0.1, 1 and 10 mg/kg of risperi-
done (Fig. 2; 5C).
Effects of olanzapine and risperidone on the external ure-
thral sphincter (Tables 2 and 3)
The EMG recorded from the urethral sphincter during
bladder contractions also showed changes after risperi-
done or olanzapine. Phase 1 of the EMG, occurring dur-
ing the initial rise in bladder pressure during a
contraction, was significantly decreased by olanzapine at
0.1 and 1 mg/kg to 76 (±1.9) and 47 (±6.0) percent of the
control value (Fig. 1F;1H; 6A). However, risperidone had
no significant effect on the EMG during phase 1 (Fig 6A).
Phase 2, which corresponds to the occurrence of high fre-
quency oscillations, showed significant decreases in the
integrated EMG following olanzapine or risperidone ad-
ministration. 0.1 mg/kg of olanzapine significantly de-
creased the overall EMG during this phase to 42 (±11.4)%
of the control value, and 1.0 mg/kg of olanzapine abol-
ished the bursting pattern of EMG (Fig 1G;1H; Fig 6B).
While risperidone also decreased the Phase 2 EMG, the
maximal decrease was 47 (±12.7)% at 1.0 mg/kg when
compared to control (Fig 6B) and the bursting pattern
was not abolished. At 10 mg/kg of risperidone, the phase
2 EMG was 71 (± 22) % and was not significantly different
from vehicle.
Phase 3 of the EMG during a bladder contraction also
showed significant changes following olanzapine or risp-
eridone (Fig 6C). Both drugs significantly decreased the
amount of integrated EMG but 0.1 mg/kg olanzapine
had a more profound effect (Fig 6C), reducing the EMG
to 35 (±5.2) % of the control value at 1.0 mg/kg compared
to 68 (±8.0) % of control after a similar dose of risperi-
done. At 10 mg/kg of risperidone the EMG was 73 (± 9.0)
% of vehicle.
Finally, while risperidone had no effect on the amplitude
of the EMG bursts occurring the expulsion phase (Fig 1;
Fig 6D), olanzapine abolished bursting of the EMG at 1.0
mg/kg in all animals tested (Fig 1H; 6D).
Effects of olanzapine and risperidone on blood pressure
Both olanzapine and risperidone decreased mean arteri-
al pressure (MAP) in anesthetized rats (Fig. 7). Risperi-
done produced significant effects at all the doses tested,
with a maximum drop in MAP of approximately 46 mm
Hg at 1 mg/kg (Mean = 44 mm Hg; SEM ±1.37). Olanza-
pine showed a significant decrease in MAP at 1.0 mg/kg
with a maximum drop of approximately 26 mm Hg
(Mean = 55 ± 3.76 mm Hg). In two animals where olan-
zapine was administered at 10 mg/kg, there was no fur-
ther reduction in MAP (Mean = 57 ± 4.95 mm Hg),
however, significant respiratory depression was ob-
served and therefore we excluded this dose for the re-
maining animals receiving olanzapine.
Table 3: Effects of cumulative doses of risperidone on urodynamic and EMG parameters in anesthetized rats. Values are Mean ± S.E.M.
Urodynamic parameters EUS EMG parameters
Dose BC (ml) MV (ml) RV (%) PT  PP  CT  ET  HFO Phase 1 Phase 2 Phase 3 Burst
(mg/kg) (mm Hg) (mm Hg) (sec) (sec) (mm Hg) (%) (%) (%) Amp.
(%)
Control 0.35 0.27 21 2.4 11.5 18.5 3.6 1.6 100 100 100 100
(±0.097) (±0.072) (±5.6) (±0.62) (±0.95) (±1.43) (±0.83) (±0.19)
0.01 0.38 0.17 47** 2.8 11.7 19.3 2.7 1.3 100 76 91 
(±8.4)
105
(±0.080) (±0.033) (±9.2) (±0.72) (±1.0) (±1.97) (±0.49) (±0.12) (±11.5) (±14.7) (±3.4)
0.1 0.38 0.10* 70** 3.4 11.7 19.4 1.5** 1.0* 84 50* 78* 80
(±0.055) (±0.019) (±7.8) (±0.44) (±0.82) (±1.94) (±0.34) (±0.22) (±11.7) (±12.3) (±10.1) (±19.6)
1 0.40 0.12** 67** 5.0* 12.4 18.6 1.4** 0.9** 74 47* 68** 76
(±0.060) (±0.016) (±5.8) (±1.02) (±1.16) (±2.6) (±0.35) (±0.18) (±13.2) (±12.7) (±8.0) (±14.0)
10 0.54 0.19 60** 5.8** 13.7** 17.2 2.2* 1.1* 81 71 (±22) 73** 84
(±0.080) (±0.036) (±7.7) (±1.02) (±1.34) (±0.96) (±0.46) (±0.22) (±15.2) (±9.0) (±14.6)
*
* p < 0.05; ** p < 0.01BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
Figure 2
Representative traces of the effects of cumulative doses of risperidone on the CMG and external urethral sphincter EMG of
anesthetized rats (n = 7). A & B) CMG after saline administration. C & D) 0.01 mg/kg of risperidone did not affect expulsion
time although residual volume was significantly increased (Table 3; Fig 3C). E & F) At 0.1 mg/kg, risperidione caused a reduction
in the amplitude of the HFO and the expulsion time. Larger doses of risperidone (1 mg/kg, G & H; 10 mg/kg, I & J) continued to
depress the expulsion time and reduced the external urethral sphincter EMG. Note that the HFO were not abolished, unlike
the results obtained with olanzapine. Calibration bar: A,C,E,G,I = 1 min; B,D,F,H,J = 1 sec.BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
Effects of olanzapine and risperidone on bladder contrac-
tions elicited by electrical stimulation of the pelvic nerve
Prolonged electrical stimulation of the pelvic nerve elic-
its a sustained bladder contraction with two compo-
nents. An initial rise in bladder pressure (Phase I; Fig.
8A) that is resistant to muscarinic blockade and a sus-
tained part of the contraction (Phase II or plateau phase)
that is very sensitive to anti-muscarinic agents [20,21].
Olanzapine at 1 and 10 mg/kg reduced the amplitude of
Phase I to 79 and 74% of the control values, respectively
(Fig. 8A;B). Risperidone, on the other hand, significantly
increased the amplitude of phase I after 10 mg/kg (116%
of control).
Figure 3
Effects of cumulative doses of olanzapine and risperidone on
bladder capacity, micturition volume and residual. A) Only
the highest dose of risperidone (10 mg/kg) increased bladder
capacity. Olanzapine had no effect. B) Both olanzapine and
risperidone significantly decreased the micturition volume
(0.1 and 1.0 mg/kg). C) All doses of risperidone increased the
residual volume whereas olanzapine resulted in significant
increases at 0.1 and 1.0 mg/kg. * = p < 0.05; ** = p < 0.01
Figure 4
Effects of cumulative doses of olanzapine and risperidone on
pressure threshold and peak pressure during cystometro-
grams. A) Olanzapine had no significant effects on the pres-
sure threshold. Risperidone, however, increased PT at 1 and
10 mg/kg. B) Olanzapine had no effect on peak pressure. Ris-
peridone significantly increased PP only at the highest dose
(10 mg/kg). * = p < 0.05; ** = p < 0.01BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
The plateau phase, or phase II of the pelvic nerve in-
duced bladder contraction was significantly reduced by
olanzapine (Fig. 8A; 6C). At 1 and 10 mg/kg, the re-
sponse was 47 and 33% of the control values, respective-
ly. Risperidone had no effect on Phase II amplitude (Fig.
8A; 8C).
Discussion
Similar to our findings with clozapine [7], olanzapine
and to a lesser extent risperidone, altered several urody-
namic parameters measured during cystometry and also
inhibited the EMG recorded from the external urethral
sphincter.
Effects of olanzapine and risperidone on urodynamic pa-
rameters and the external sphincter EMG
Both olanzapine and risperidone are compounds with
relatively high oral bioavailability. Clinically effective
doses of olanzapine (10–15 mg/day; 18.4–30.6 ng/ml
plasma concentration [22–24]) or risperidone (3–6 mg/
day; 15–30.8 ng/ml combined plasma concentration of
risperidone and 9-hydroxy-risperidone [25]) correspond
well with the dose of 1.0 mg/kg (equivalent to 12.5 ng/
ml) in the present study.
Both neuroleptics markedly decreased the micturition
volume, expulsion time, and amplitude of the HFO while
residual volume increased. Most of the effects of either
neuroleptic occurred at doses of 0.1 and 1.0 mg/kg. Olan-
zapine appeared to have a greater maximal effect than
risperidone. At the highest dose of risperidone (10 mg/
kg) there was less of an effect for the urodynamic param-
eters mentioned above. This is an interesting observa-
tion that was not explored further in the present study.
The physiological significance is unclear since the 10 mg/
kg dose is well above the clinically effective doses of risp-
eridone.
Olanzapine did not have an effect on bladder capacity or
pressure threshold while risperidone increased both al-
though only at the highest doses. Clozapine, on the other
hand, was observed previously to increase bladder ca-
pacity and pressure threshold [6,7]. Olanzapine had no
effect on bladder peak pressure during contraction and
only the highest dose of risperidone showed an increase
in pressure (119% of control). The increase in pressure
after the highest dose of risperidone was interesting and
was also observed following electrical stimulation of the
pelvic nerve suggesting a possible peripheral mecha-
nism.
Olanzapine, but not risperidone, decreased the integrat-
ed EMG recorded during the beginning of a bladder con-
traction (Phase 1; comparable to the guarding reflex).
Both neuroleptics decreased the EMG during phase 2,
Figure 5
Effects of cumulative doses of olanzapine and risperidone on
contraction time, expulsion time and the amplitude of the
high frequency oscillations. A) Neither olanzapine nor risp-
eridone significantly changed the contraction time. B) The
expulsion time was significantly decreased by both olanzapine
and risperidone. Olanzapine abolished the expulsion time at
1.0 mg/kg. C) The amplitude of the HFO was significantly
decreased by both olanzapine and risperidone. Olanzanpine
had a greater effect, abolishing the HFO at 1.0 mg/kg,
whereas risperidone decreased the amplitude to approxi-
mately 50% of control values. * = p < 0.05; ** = p < 0.01BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
where high frequency oscillations occur in the bladder
pressure along with bursting in the EUS, with the highest
dose of olanzapine (1.0 mg/kg) abolishing the HFO and
the bursting pattern. The integrated EMG recorded dur-
ing the end of the bladder contraction (Phase 3) was also
decreased by both neuroleptics, with olanzapine reduc-
ing it to 69% and 35% at 0.1 and 1.0 mg/kg, respectively,
whereas the maximal effect for risperidone was observed
at 1 mg/kg (68%).
Finally, neither neuroleptic decreased the amplitude of
the individual bursts of EMG recorded during phase 2,
except for the largest dose of olanzapine (1 mg/kg) that
abolished the bursting pattern.
Therefore, as was the case for urodynamic parameters,
although both neuroleptics decreased the activity of the
external urethral sphincter (as reflected in the integrated
EMG), it appears that the effects of olanzapine were
greater than those of risperidone. As was the case for
some urodynamic parameters, the highest dose of risp-
eridone showed a parabolic effect for some of the EMG
parameters.
Blockade of the external urethral sphincter in anesthe-
tized rats results in a disappearance of the HFO from the
bladder pressure recording as well as a disappearance of
the bursting pattern of the EUS EMG observed during
HFO [26–28]. In addition, there is a decreased ability of
Figure 6
Effects of olanzapine and risperidone on the integrated EMG recorded from the external urethral sphincter. A) The EMG dur-
ing Phase 1, which may be analogous to the "guarding reflex" was significantly decreased by olanzapine (0.1 and 1.0 mg/kg). Ris-
peridone had no effect. B) Both olanzapine and risperidone had a significant effect on the EMG during Phase 2. Olanzapine had
greater effects, essentially abolishing the bursting pattern of the EMG after 1.0 mg/kg. C) Both olanzapine and risperidone
decreased the EMG during phase 3. However, olanzapine had a greater effect (0.1 and 1.0 mg/kg) than risperidone. D) The
amplitude of the individual bursts of EMG observed during phase 2 were not significantly affected by risperidone. Olanzapine
had no effect at 0.1 mg/kg but at 1.0 mg/kg abolished the bursting pattern.BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
the bladder to empty as evidenced by a decreased mictu-
rition volume and an increased residual volume
[26,27,29]. Therefore, inhibition of the external urethral
sphincter, as was the case for the two neuroleptics in the
present study and also for clozapine in our earlier study
[7], might provide an important mechanism by which the
bladder is rendered less effective in emptying and there-
fore altering other urodynamic variables resulting in de-
creased micturition volume and increased residual
volume in rats.
Possible neuropharmacological mechanisms for the effect 
of olanzapine and risperidone on the lower urinary tract
We tested for peripheral antimuscarinic actions of both
neuroleptics by examining their effects on bladder con-
tractions elicited by electrical stimulation of the pelvic
nerve. In this preparation, olanzapine but not risperi-
done reduced the initial contraction amplitude (Phase I)
somewhat and markedly depressed the prolonged con-
traction phase (Phase II; Fig. 8) that is thought to be me-
diated by muscarinic receptors [20,21]. During
cystometry, however, neither olanzapine nor risperidone
affected the peak pressure during bladder contraction.
Therefore, although olanzapine had a peripheral effect
on bladder contraction amplitude, as might be expected
from its antimuscarinic effects, this effect is not reflected
in the peak contraction pressures observed during
cystometry. This discrepancy is probably due to the fact
that during a bladder contraction against a closed outlet
Figure 7
Mean arterial pressure changes as a result of olanzapine and
risperidone. Both of these drugs caused a marked drop in
mean arterial pressure (MAP), with risperidone having a
larger effect than olanzapine. All doses of risperidone
resulted in significant decreases in MAP, whereas only the
highest dose of olanzapine (1.0 mg/kg) caused a significant
decrease in MAP. * = p < 0.05; ** = p < 0.01.
Figure 8
Peripheral anti-muscarinic effects of olanzapine and risperi-
done. A) Prolonged (60 sec) electrical stimulation of the cut
distal end of the pelvic nerve results in a bladder contraction.
The amplitude of the initial rise of the contraction (Phase I) is
resistant to muscarinic blockade. The plateau phase (Phase
II), however, is very sensitive to anti-muscarinic agents. After
10 mg/kg of olanzapine, Phase I is somewhat decreased, but
phase II is markedly reduced. After 10 mg/kg of risperidone,
Phase I is larger than control, while phase II is unchanged. B)
Phase I amplitude as a function of cumulative doses of olanza-
pine and risperidone. Olanzapine decreased the amplitude at
1 and 10 mg/kg. Risperidone did not reduce the amplitude
but it significantly increased the amplitude at 10 mg/kg. C)
Phase II amplitude was markedly reduced by 1 and 10 mg/kg
of olanzapine whereas risperidone had no effect. * = p < 0.05;
** = p < 0.01.BMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
(electrical stimulation of the pelvic nerve) higher pres-
sures were developed than were observed during
cystometry when the outlet was not obstructed. Since the
clinically effective dose of olanzapine (10–15 mg/day;
18.4–30.6 ng/ml plasma concentration [22–24]) is
greater than the first dose observed to produce signifi-
cant peripheral antimuscarinic effects in this study (1.0
mg/kg; equivalent to 12.5 ng/ml plasma concentration) a
possible peripheral anti-muscarinic on the bladder dur-
ing olanzapine therapy remains a concern.
Muscarinic blockade with atropine decreased micturi-
tion pressure and micturition volume, while increasing
residual volume [30] and bladder capacity [31]. Similar-
ly, central administration of atropine decreased peak
pressure and voiding efficiency while increasing bladder
capacity in awake rats [32]. Thus it is possible that cen-
tral and/or peripheral muscarinic blockade by olanzap-
ine may have contributed to some of the changes
observed in these parameters in the present study.
Muscarinic blockade was also reported to decrease the
EUS EMG in all phases of the bladder contraction [33].
However, another study showed no effect on the EUS
EMG following muscarinic antagonism [34]. Therefore,
the exact role of muscarinic blockade on the activity of
the EUS in the rat is unclear.
It is tempting to propose that the greater effect of olanza-
pine on the EUS may be due to its antimuscarinic activi-
ty, which risperidone does not have. In fact, clozapine
has a greater affinity for muscarinic receptors than olan-
zapine [11] and clozapine was also able to decrease the
EMG and abolish the bursting pattern during phase 2.
Whether muscarinic blockade affects the activity of the
EUS by acting on central or peripheral sites remains to
be determined. A direct inhibitory action of olanzapine
on the EUS muscle itself is not expected and was not seen
with clozapine [7]. However, antimuscarinic effects
alone cannot account for all of the effects of olanzapine
on the EUS, since risperidone had a similar effect al-
though not quite as pronounced and risperidone has lit-
tle or no affinity for muscarinic receptors [16]. Therefore,
antagonism of other transmitter systems, e.g. D2, alpha1,
5-HT2, remains as an explanation of the effects of these
neuroleptics on urodynamic variables [6].
Selective antagonism of D2 receptors only modestly re-
duced the amplitude of HFO without affecting any other
urodynamic parameters [6,35]. Therefore, it is possible
that olanzapine and risperidone decrease the amplitude
of the HFO, at least partly, through antagonism of D2 re-
ceptors.
In anesthetized rats, doxazosin (alpha 1 adrenergic re-
ceptor antagonist) administered systemically, increased
micturition volume, bladder capacity, residual volume
and micturition frequency while decreasing peak pres-
sure [36]. Only an increase in the micturition frequency
was observed after spinal administration of doxazosin
[37]. Both olanzapine and risperidone have moderate af-
finity for the alpha 1 adrenergic receptor (Table 1), there-
fore it is possible that some of the effects observed in the
present study were due to central and/or peripheral an-
tagonism of alpha 1 adrenergic receptors by these drugs.
The decreases observed in MAP suggest a possible pe-
ripheral alpha1 effect. However, we did not observe a de-
crease in the peak pressure as would have been predicted
from previous studies using selective alpha 1 antagonism
[36]. In addition, bladder capacity was not affected ex-
cept at the highest dose of risperidone tested. Urinary in-
continence as a result of olanzapine [12] or clozapine [15]
therapy was treated effectively with ephedrine (alpha
adrenergic receptor agonist), suggesting a possible
alpha1 effect. However, alpha1a-adrenoceptor gene poly-
morphism was found to play no role in clozapine-in-
duced urinary incontinence [38].
In terms of the effects on the EUS, alpha 1 antagonists
have been shown to inhibit the EUS in the cat [39–41]
but not in the anesthetized rat [42].
Finally, both olanzapine and risperidone posses affini-
ties to several serotonin receptor subtypes (Table 1). In
cats, serotonin antagonists caused a decrease in bladder
capacity [43] however in anesthetized rats, serotonin an-
tagonism did not have an effect on micturition [44]. Re-
cently, a selective 5-HT1A receptor antagonist (WAY-
100635) was reported to inhibit bladder contractions in
rats [45] yet another report only observed an increase in
the pressure threshold [46]. Olanzapine and risperidone
have only low to modest affinity for the 5-HT1A receptor,
and higher affinities for the 5-HT2A and 5-HT2C recep-
tors [11,12]. Serotonin 5-HT2 and 5-HT3 receptors facil-
itate pudendal reflexes in the cat [47,48], therefore it is
possible that antagonism of these receptors may block
the EUS in the anesthetized rat. Given the modest role of
serotonin receptors in micturition in anesthetized rats, it
remains to be determined whether the effects observed
here were due to anti-serotonergic effects of these neu-
roleptics.
Clinical implications
While there are several reports of urinary disturbances
following clozapine therapy [3,10,15], there are relatively
few reports of urinary incontinence with risperidone or
olanzapine. In one report, twenty-eight (28%) of patients
on risperidone developed at least transient urinary in-
continence, compared to 13% before starting treatmentBMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
[18]. Other reports also suggest urinary incontinence as-
sociated with risperidone therapy [17,19].
To date, only one case report of urinary incontinence
with olanzapine therapy that resolved with ephredrine
was found in the literature [14]. In the present study,
olanzapine had more profound effects on urodynamic
parameters and the EUS than risperidone and therefore
the incidence of urinary disturbances in clinical practice
would be predicted to be higher. Olanzapine is a newer
compound than clozapine or risperidone and therefore, a
larger incidence of urinary symptoms with olanzapine
therapy may await a larger sampling.
Finally, possible side effects of neuroleptics, such as uri-
nary retention, may be predicted from binding studies
using human brain tissue [12] if antimuscarinic affinities
will correspond to antimuscarinic effects on the bladder.
However, olanzapine and risperidone may also result in
urinary disturbances by their influence on central path-
ways mediating bladder contractions or coordinating ex-
ternal urethral sphincter, as may have been the case in
the present study. Such effects may not be readily appar-
ent or predictable from receptor binding studies.
Conclusions
Olanzapine and to a lesser extent risperidone, altered
several micturition parameters and they inhibited the
external urethral sphincter in the anesthetized rat. These
effects resulted in a decreased effectiveness of the blad-
der to empty as evidenced by a decreased micturition
volume and an increase in the residual volume, and a de-
creased activity of the external urethral sphincter. Al-
though olanzapine also showed peripheral anti-
muscarinic effects on bladder contractions, risperidone
did not. Therefore, peripheral anti-muscarinic effects
alone cannot explain all the changes observed with these
drugs and they might reflect central effects on micturi-
tion pathways.
Materials and Methods
The experiments were conducted in compliance with the
USDA Animal Welfare Act and amendments thereto and
the revised Guide for the Care and use of Laboratory An-
imals DHEW (NIH) and were approved by the Animal
Studies Subcommittee of the Bay Pines Veterans Admin-
istration Medical Center.
Surgical procedures have been described in detail else-
where [7]. Briefly, rats (female Sprague-Dawley; n = 20;
200–250 g; Harlan; IN) were anesthetized with haloth-
ane and placed on a heating pad. A catheter (PE-50) was
introduced into the jugular vein to administer urethane
(1.1 g/kg) over a period of 20 minutes while decreasing
the level of halothane to prevent respiratory depression.
After an abdominal incision, both ureters were exterior-
ized (PE 10) and a catheter (PE-90) was introduced into
the bladder dome and tied in place with a purse string su-
ture. A catheter (PE-50) was introduced into the right
femoral artery for blood pressure recording. Stainless-
steel wires (0.003 in.; A-M Systems; WA) insulated ex-
cept at the tip were introduced into the external urethral
sphincter for EMG recording.
Urodynamic Studies
The bladder was emptied and allowed to equilibrate to
air pressure for 5 minutes before beginning each
cystometrogram. Room temperature saline was infused
into the bladder (0.11 ml/min) while recording bladder
pressure and the infusion was stopped when a contrac-
tion occurred. Volume expelled was determined by plac-
ing cotton gauze at the urinary meatus and weighing
before and after micturition. External urethral sphincter
EMG (EUS-EMG) was recorded throughout the
cystometrogram and for sometime after the filling had
stopped. Cumulative doses of olanzapine (provided as a
courtesy by Ely Lilly, Indianapolis; vehicle, 0.01, 0.1, 1
mg/kg; n = 5) and risperidone (RBI; vehicle, 0.01, 0.1, 1,
10 mg/kg; n = 7) were administered i.v. at approximately
10 minute intervals. The plasma half-life of olanzapine
and risperidone are 2.5 and 15 hr, respectively [25,49].
Both drugs were dissolved in a minimal amount of 0.1 N
HCl, and brought up to volume with saline (final pH = 6).
Cystometrograms were started approximately 3 minutes
after each drug administration.
Bladder contractions induced by pelvic nerve stimulation
In order to determine the direct peripheral effects of
these drugs on the bladder, the distal end of a pelvic
nerve was stimulated electrically to elicit a bladder con-
traction (n = 8). Both hypogastric and pelvic nerves were
cut before they entered the major pelvic ganglion and a
tie was placed around the urinary meatus to preserve is-
ovolumetric conditions. After infusing 0.1–0.2 ml into
the bladder the distal, cut end of the pelvic nerve was
stimulated with a long train (5 Hz; 1 msec pulse width;
60 sec train; 30–300 (uamps) to elicit a prolonged con-
traction displaying two phases: Phase I, a rapid contrac-
tion and Phase II, a plateau phase [20,21]. Phase I is
resistant to atropine, and therefore is mostly due to non-
adrenergic, non-cholinergic activation, whereas Phase II
is highly sensitive to muscarinic blockade [21]. Olanzap-
ine (n = 4) and risperidone (n = 4) were administered
(0.01,0.1,1 and 10 mg/kg; i.v.) and the stimulations were
repeated at 10 minutes intervals. At the end of each ex-
periment, all rats were overdosed with urethane i.v.
Data analysis
Bladder pressure and EUS-EMG during the cystometro-
grams were displayed in an electronic chart recorder (RCBMC Pharmacology 2001, 1:4 http://www.biomedcentral.com/1471-2210/1/4
Electronics; Goleta, CA) and analyzed off-line (Dataview,
W.J. Heitler, U. St Andrews, Scotland). The following pa-
rameters were examined from the cystometrogram as
described in detail earlier [7]: bladder capacity (amount
of fluid infused to elicit a contraction); micturition vol-
ume (amount of fluid expelled); residual volume ([blad-
der capacity – micturition volume]/ [bladder capacity]);
pressure threshold (pressure at which contraction be-
gins); peak pressure (maximal pressure during contrac-
tion); contraction time; expulsion time (time between
peak pressure and end of high frequency oscillations);
amplitude of high frequency oscillations. The EMG activ-
ity was examined by dividing the bladder contraction
into three phases in a modification of the technique of
Chien et al. [33] a contraction phase (phase 1); an expul-
sion phase (phase 2) and a closing phase (phase 3).
The raw EMG was rectified, integrated (0.5 second bin)
and the area under curve of the EMG corresponding to
each phase of the bladder contraction was measured
(Sigma Scan/Image; Jandel Scientifics, San Rafael, Ca).
Drug effects were calculated as percent of control.
In the case of bladder contractions induced by pelvic
nerve stimulation, the amplitude of phase A and Phase B
were compared to drug free control values.
Values are presented as Mean ± S.E.M. Repeated meas-
ures ANOVA (GB Stat; Dynamic Microsystems; MD)
were performed on all parameters and when statistical
significance (p < 0.05) was obtained, comparisons be-
tween control and different drug dosages were made us-
ing Fisher's protected t-test [50].
Abbreviations
EMG = electromyogram EUS = external urethral sphinc-
ter MAP = mean arterial pressure CMG = cystometro-
gram BC = bladder capacity PT = pressure threshold PP
= peak pressure ET = expulsion time HFO = high fre-
quency oscillations MV = micturition volume RV = resid-
ual volume CT = contraction time
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